Theravance SVP has 13,929 shares withheld for taxes

Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a tax-related share disposition connected to the vesting of restricted stock units.

Rhea-AI Filing Summary

Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a tax-related share disposition connected to the vesting of restricted stock units. On this Form 4, 13,929 ordinary shares were withheld at a price of $19.66 per share to satisfy tax obligations, in a transaction with the issuer rather than through the open market. Following this tax-withholding event, Farnum directly owned 263,766 ordinary shares.

Insider Trade Summary

Exercise Price or Tax Liability: 13,929 shares

Exercise Price or Tax Liability 1 txn

Insider Farnum Rhonda

Role SVP, COMM & MEDICAL AFFAIRS

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	13,929	$19.66	$274K

Holdings After Transaction: Ordinary Shares — 263,766 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Theravance Biopharma (TBPH) report for Rhonda Farnum?

Theravance Biopharma reported a tax-withholding disposition by SVP Rhonda Farnum. The company withheld 13,929 ordinary shares upon vesting of restricted stock units to cover tax obligations, with the shares transferred back to the issuer rather than sold on the open market.

How many Theravance Biopharma (TBPH) shares were involved in Rhonda Farnum’s Form 4 filing?

The Form 4 shows 13,929 ordinary shares were withheld. These shares were used to satisfy tax liabilities arising from the vesting of previously granted restricted stock units, according to the footnote, and were not part of an open market transaction or discretionary sale.

Was Rhonda Farnum’s Theravance Biopharma (TBPH) transaction an open market sale?

No, the transaction was not an open market sale. The filing states the 13,929 withheld shares were transferred to the issuer to cover tax obligations from restricted stock unit vesting, rather than being sold through the market to outside buyers.

What price per share was used for the Theravance Biopharma (TBPH) tax-withholding transaction?

The reported price per share for the tax-withholding disposition was $19.66. This value is applied to the 13,929 ordinary shares withheld to satisfy Rhonda Farnum’s tax obligations on the vesting restricted stock units, as reflected in the Form 4 data fields.

How many Theravance Biopharma (TBPH) shares does Rhonda Farnum hold after this Form 4 event?

After the tax-withholding disposition, Rhonda Farnum directly owned 263,766 ordinary shares. This post-transaction holding reflects her remaining position following the issuer’s withholding of 13,929 shares to meet tax liabilities from vested restricted stock units.

What does the transaction code “F” mean in the Theravance Biopharma (TBPH) Form 4?

The transaction code “F” indicates payment of an exercise price or tax liability by delivering securities. In this case, 13,929 shares were withheld by Theravance Biopharma to satisfy Rhonda Farnum’s tax obligations tied to vesting restricted stock units, not a voluntary market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 07:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farnum Rhonda

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, COMM & MEDICAL AFFAIRS

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/20/2026		F		13,929(1)	D	$19.66	263,766	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.